Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $868.45M |
| Net Income (Most Recent Fiscal Year) | $158.69M |
| PE Ratio (Current Year Earnings Estimate) | 9.12 |
| PE Ratio (Trailing 12 Months) | 12.29 |
| PEG Ratio (Long Term Growth Estimate) | 0.20 |
| Price to Sales Ratio (Trailing 12 Months) | 1.96 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.94 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 9.59 |
| Pre-Tax Margin (Trailing 12 Months) | 21.97% |
| Net Margin (Trailing 12 Months) | 16.20% |
| Return on Equity (Trailing 12 Months) | 17.19% |
| Return on Assets (Trailing 12 Months) | 11.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.58 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.15 |
| Inventory Turnover (Trailing 12 Months) | 35.71 |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.55 |
| Earnings per Share (Most Recent Fiscal Year) | $2.71 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.48 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.89M |
| Free Float | 51.52M |
| Market Capitalization | $1.77B |
| Average Volume (Last 20 Days) | 0.75M |
| Beta (Past 60 Months) | 0.97 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.23% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |